Masand P S, Gupta S
Department of Psychiatry, SUNY Health Science Center at Syracuse 13210, USA.
Depress Anxiety. 1997;6(3):119-23. doi: 10.1002/(sici)1520-6394(1997)6:3<119::aid-da5>3.0.co;2-8.
We describe the use of dexfenfluramine (Redux) in six patients with mood disorders (bipolar disorder = 3; major depression = 3) who developed significant weight gain as a result of their psychotropics. All patients were females with an age range of 27-58 years. The duration of the trial varied from 3 to 20 weeks, with the dexfenfluramine dosage being 15 mg twice daily. Weight loss ranged from 2 to 23 pounds. None of the patients had any evidence of primary pulmonary hypertension or serotonin syndrome, despite being on serotonergic agents such as fluoxetine, paroxetine, and sertraline.
我们描述了右芬氟拉明(Redux)在6例因使用精神药物而体重显著增加的情绪障碍患者(双相情感障碍3例;重度抑郁症3例)中的应用。所有患者均为女性,年龄在27至58岁之间。试验持续时间为3至20周,右芬氟拉明剂量为每日两次,每次15毫克。体重减轻范围为2至23磅。尽管这些患者正在服用氟西汀、帕罗西汀和舍曲林等血清素能药物,但均未出现原发性肺动脉高压或血清素综合征的迹象。